EXTRA ON THE TRUTH ABOUT KERA'S VALUATION!
FROM THE LATEST LOSSES REPORT:
Revenues totaled $1.9 million for the fourth quarter and consisted largely of sales from surgical instrument sets and start-up inventories of Intacs for correcting mild nearsightedness (myopia). This compares to revenues of $4.19 million in the third quarter of 1999. A decrease in revenue of 55%.
WOW, THIS COMPANY IS SUPPOSED TO BE GROWING NOT SHRINKING. THE ONLY THING GROWING IS CASH OUT AND NET LOSSES, HERE'S MORE FROM THE LATEST PRESS RELEASE:
Net loss for the 1999 fourth quarter was $9.5 million versus $7.2 million for the fourth quarter in 1998.
The net loss for the year was $27.3 million compared to a loss of $24.0 million in 1998.
NET REVENUES FOR 2000 ARE EXPECTED TO BE AROUND $2.3 MILLION, WITH NET LOSSES EXPECTED TO BE ABOUT $48 MLN. BUT WAIT, HOW COULD THAT BE? THAT'S BECAUSE TRAINING REVENUES ARE FINISHED AND NOT MANY DOCTORS NEED ANY REPLACEMENT INTACS BECAUSE PROCEDURES PERFORMED IS NOT INCREASING BUT DECREASING BECAUSE DOCTORS ARE HAVING TO DEAL WITH PATIENTS COMPLAINING OF PAIN. PLUS LASIK COSTS ONLY $900 PER EYE NOW! INTACS ARE ABOUT TO BURN JUST LIKE IRIDIUM'S SATELLITES. IN A FEW MONTHS KERA WILL JUST BE A BITTER MEMORY!
IF KERA STOCK SELLS FOR 4 TIMES REVENUES AS IT DOES NOW, THE SHARE PRICE WILL BE 50 CENTS! THAT'S GENEROUS, BECAUSE THE PRICE TO SALES RATIO COULD ACTUALLY BE LESS THAN 1 WHEN EVERYONE SEES WHERE THIS COMPANY IS HEADED, meaning the stock price would be pennies AND SOON.
THAT'S WHERE THE PRICE WILL BE BY YEAR END. THEN KERA WILL GO INTO BANKRUPTCY.
OH TOO BAD, BOSS, BOSS, DA PAIN, DA PAIN! |
